Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study: Clear cell papillary RCC has indolent course

Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005

Key clinical point: Clear cell papillary renal cell carcinoma (CCPRCC) is a distinct renal tumor type with an apparently indolent clinical course.

Major finding: There were no cases of local recurrence or distant metastasis of CCPRCC after a mean of 49.7 months of follow-up (range 12-119 months).

Study details: Retrospective case study of 25 patients diagnosed and treated at a single center.

Disclosures: The investigators did not report a study funding source. They reported having no conflicts of interest relevant to the subject matter or materials discussed in the article.

Read the article.

Citation:

Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005